Literature DB >> 22945795

Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study.

Seth A Kareus, Karla P Figueroa, Lisa A Cannon-Albright, Stefan M Pulst.   

Abstract

OBJECTIVE To use a statewide population-based genealogic database to evaluate the relationship between Parkinson disease (PD) and cancer subtypes. DESIGN Using a computerized genealogy for the Utah pioneers and their descendants linked to a statewide cancer registry and statewide death certificates, we estimated relative risks for cancer in individuals with PD listed on their death certificate, and in their first-degree, second-degree, and third-degree relatives. SETTING Utah Cancer Registry. PARTICIPANTS Approximately 2.3 million individuals in the Utah genealogic resource, including death certificates of 2998 individuals with PD listed as a cause of death from 1904 to 2008 and information on 100 817 individuals with a cancer diagnosis in the Utah Cancer Registry. RESULTS Melanoma and prostate cancer were the only cancers observed in significant excess among PD cases; colorectal, lung, pancreas, and stomach cancers were observed in deficit. A significantly increased risk for prostate cancer was observed in the PD population as well as among their relatives. A reciprocal significantly increased risk for PD was also found in the 22 147 prostate cancer cases and their relatives. A significantly elevated risk for melanoma was found in the Utah PD population as well as in their relatives. A reciprocal significantly increased relative risk for PD was found in 7841 Utah melanoma cases and their relatives. CONCLUSIONS Our study identified a novel association between PD and prostate cancer, which extended to first-degree, second-degree, and third-degree relatives. We also confirmed the reported risk association for melanoma in patients with PD; we extended the finding to include a significantly increased risk in relatives. These results strongly support a genetic link. This conclusion is further strengthened by observation of the reciprocal relationship, an increased risk for PD in relatives of individuals with melanoma or prostate cancer.

Entities:  

Year:  2012        PMID: 22945795     DOI: 10.1001/archneurol.2012.2261

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  29 in total

1.  Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.

Authors:  Ilir Agalliu; Roberto A Ortega; Marta San Luciano; Anat Mirelman; Claustre Pont-Sunyer; Kathrin Brockmann; Dolores Vilas; Eduardo Tolosa; Daniela Berg; Bjørg Warø; Amanda Glickman; Deborah Raymond; Rivka Inzelberg; Javier Ruiz-Martinez; Elisabet Mondragon; Eitan Friedman; Sharon Hassin-Baer; Roy N Alcalay; Helen Mejia-Santana; Jan Aasly; Tatiana Foroud; Karen Marder; Nir Giladi; Susan Bressman; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2019-07-26       Impact factor: 10.338

2.  The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival.

Authors:  Xiqun Chen; Hongxiang Chen; Waijiao Cai; Michael Maguire; Bailiu Ya; Fuxing Zuo; Robert Logan; Hui Li; Katey Robinson; Charles R Vanderburg; Yang Yu; Yinsheng Wang; David E Fisher; Michael A Schwarzschild
Journal:  Ann Neurol       Date:  2017-01-23       Impact factor: 10.422

3.  Parkinson's disease and colorectal cancer risk-A nested case control study.

Authors:  Ben Boursi; Ronac Mamtani; Kevin Haynes; Yu-Xiao Yang
Journal:  Cancer Epidemiol       Date:  2016-05-24       Impact factor: 2.984

4.  Risk of Parkinson's disease after colectomy: longitudinal follow-up study using a national sample cohort.

Authors:  Young-Ju Kim; Chang-Min Lee; Seongheon Kim; Jae-Won Jang; Seo-Young Lee; Seung-Hwan Lee
Journal:  J Neurol       Date:  2019-11-05       Impact factor: 4.849

5.  Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Authors:  Ilir Agalliu; Marta San Luciano; Anat Mirelman; Nir Giladi; Bjorg Waro; Jan Aasly; Rivka Inzelberg; Sharon Hassin-Baer; Eitan Friedman; Javier Ruiz-Martinez; Jose Felix Marti-Masso; Avi Orr-Urtreger; Susan Bressman; Rachel Saunders-Pullman
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

6.  News from epidemiological studies on Alzheimer's and Parkinson's disease: a personal perspective.

Authors:  Massimo Musicco; Katie Palmer
Journal:  J Neurol       Date:  2013-06-07       Impact factor: 4.849

7.  Treatment with diphenyl-pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death.

Authors:  Elisa Turriani; Diana F Lázaro; Sergey Ryazanov; Andrei Leonov; Armin Giese; Margarete Schön; Michael P Schön; Christian Griesinger; Tiago F Outeiro; Donna J Arndt-Jovin; Dorothea Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

Review 8.  Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.

Authors:  Heather M Snyder; Tim Ahles; Stuart Calderwood; Maria C Carrillo; Honglei Chen; Chung-Chou H Chang; Suzanne Craft; Philip De Jager; Jane A Driver; Howard Fillit; David Knopman; Michael Lotze; Mary C Tierney; Suzana Petanceska; Andrew Saykin; Sudha Seshadri; Diana Shineman; Mary Ganguli
Journal:  Alzheimers Dement       Date:  2016-12-18       Impact factor: 21.566

9.  Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.

Authors:  Radu Constantinescu; Jordan Elm; Peggy Auinger; Saloni Sharma; Erika F Augustine; Laith Khadim; Karl Kieburtz
Journal:  Mov Disord       Date:  2013-12-03       Impact factor: 10.338

10.  Parkinson's disease and cancer: A register-based family study.

Authors:  Karin Wirdefeldt; Caroline E Weibull; Honglei Chen; Freya Kamel; Cecilia Lundholm; Fang Fang; Weimin Ye
Journal:  Am J Epidemiol       Date:  2013-10-18       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.